CasInvent
2 known investors
CasInvent Pharma is a Masaryk University spin-off developing proprietary, highly selective small-molecule inhibitors of the Casein Kinase 1 (CK1) family to treat therapy-resistant tumors. Its candidate compounds target indications such as acute myeloid leukemia, melanoma, triple-negative breast cancer, pancreatic cancer, and prostate cancer, and are being advanced through preclinical toward clinical development.